¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º `TkbF9N+  
.h a`)@MsZ  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ )L|C'dJ<k`  
D|"sE>  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) =J`gGDhGY-  
.dt#2a_5q  
1. ICAM-1 ([1=>Jw"  
i{P%{hVb  
2. interleukin 12(IL-12) 8KZ$ F>T]>  
.$UTH@;7  
3. tumor infiltrating lymphocyte 1x8(I&i  
<Ak:8&$O  
4. TCR/CD3 complex hl*MUD,  
xP42xv9U  
5. hematopoietin receptor family EQ6l:[  
]}_p3W "Y9  
6. individual idiotype(IdI) ysL0hwir  
4 iik5  
7. integrin <xXiJU+  
CgN]dx* `  
8. colony-stimulatory factor (CSF) #j\*Lc"Ur:  
o.p+j  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© r$94J'_  
_F! :(@}  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? }<E sS  
=" /R5fp  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ IvPA|8(  
-Mr{+pf  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ22l|!B%o  
jn0t-":  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ pHq{S;R2G  
@ARAX\F  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) Uyz;U34 oI  
]|H]9mys98  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ U{j5kX  
 ]H@v  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR)  "Nk`RsW  
.%-6&%1  
3. immunoglobulin superfamily (IgSF) XHU<4l:kl  
=e"H1^Ml  
4. selectin 2<`gs(oxXe  
V2WUM+`uT  
5. anti-idiotypic antibody (¦ÁId) 'XC&BWJ  
UXcH";*9b  
6. major histocompatibility complex(MHC) ' lQ  
EZgxSQaPH  
7. immunotolerance Z&?+&q r^  
j]cXLY  
8. biological reponse modifier(BRM) vTe$77n  
8AC. 2 v?_  
9. immune reponse gene (Ir gene) i-Ge *?  
'p|Iwtjn>  
10. reshaped antibody (or reconstituted antibody) rU2YMghE  
[~Z'xY y  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 2Be?5+  
/z.7: <gZ(  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ !?us[f=g%  
kL2Zr  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? iA^+/Lt  
%FR^[H]  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ h.}t${1ZC  
fa*H cz  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? I ]WeZ,E  
P(YG@  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ HIWmh4o/.  
W2W2WyPk  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? yBD2  
H-\ {w    
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ #.<F 5  
~y-vKCp|  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ /i~^LITH  
/qz "I-a  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? M_e$l`"G  
5?~[|iPv  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ +GPT:\*q6  
<@AsCiQF  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: 7N59B z  
1J{z}yPHc  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: 1f pS"_}  
f;tyoN0wHx  
ÃâÒßѧ : ! iPn%  
- C'X4C+  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© b\0 Q:  
Y 7t{4P  
1. CD8 o? O,nD 6  
&pY G   
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) i(f;'fb*  
\`p~b(  
3. immunoglobulin fold(Ig fold) .iN* V|n  
?5YmE(v7  
4. cadherin (Ca-dependent cell adhesion moleculers) lQ<n dt~  
'iISbOM  
5. idiotype-anti-idiotypic antibody immune network theory hC, -9c  
G* ~*2>~  
6. HLA class II antigen eW*ae;-  
oJJ k  
7. complementarity-determining region (CDR) :0j`yo:w  
<&0*5|rR  
8. perforin(or pore-forming protein ,PFP) P"_}F  
BvW gH.OX  
9. high affinity IL-2 receptor ,Ho. O7H  
;$L!`"jn  
10. artificial active immunization fQ.>G+0 I>  
"gikX/Co=  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Qp{-!*  
|wb(rua  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ<d&)|W  
tMBy ^@p  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 [5eT|uy  
z(X6%p0  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ N5Mz=UgB  
UR2)e{RXg  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ L.:QI<n  
]a|;G  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ U@5Z9/n{  
khIa9Nm  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? FY S83uq0  
_";pk  _  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ +vSE}  
]]o[fqD-Zn  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ -86:PL(I"  
E(LE*J  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ SY)$2RC+}  
iQ"F`C  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ U?j>28  
1+}Ud.v3VW  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© Bic { H  
$QBUnLOek&  
1. immunoglobulin gene rearrangement a`iAA1HJ  
N4jLbnA  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) Z`c{LYP,y"  
!z 5d+ M  
3. flow cytometry(FCM) lB~'7r`  
M?zAkHNS$  
4. carrier effect g^UWf<xp  
 F]#fl%  
5. positive selection of T lymphocytes in thymus h18y?e7MU  
%pQ o%<d  
6. mouse TH1(Th1) and TH2(Th2) subsets Rj`Y X0?+  
!PIdw~YC  
7. perforin (pore-forming protein ,PFP) ZhaOH5{9  
;}'<`(f&nX  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) hAyPaS#  
|R/50axI  
9. SH-2(src-homology region 2) n5>N9lc  
RhmVHhj  
10. Ab2¦Â (internal image) uZI a-b  
i%8 sy  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© :%MWbnVSC,  
Mwc3@  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? x)L@x Q  
X&Lt?e,&  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? =>*N W9c  
epyfgg MT  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦ÓᣠQ4q#/z  
`oBzt |f5  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ 0{F.DDiNT  
3IFU{0a`  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠLai"D[N  
90}B*3x  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) a~>h'}C>  
CI{x/ e^(  
ÃâÒßѧרҵ£º ^dv>n]?  
>qA&;M  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ ]U%Tm>s.  
sSUd;BYf  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? qa6~N3*  
6! 'Xo:p  
´«È¾²¡Ñ§×¨Òµ£º kZQ;\QL1}  
}R$%MU5::  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ .U_=LV]C  
tO7{g  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ 'oG'`ED"  
WM26-nR  
Ïû»¯×¨Òµ£º x5ia<V>=d  
0P(}e[~Z  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ 14R L++  
B|v fkX2f  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? D$HxPfDZ  
GCHssw~P'v  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ wal }[F#  
P; Ox|  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© K#jm6Xh ?E  
^gG,}GTl  
1. Fas(CD95)/FasL o=ex{g(3  
J3=jC5=J4  
2. common chain of cytokine receptor v;S JgZK  
M4| L  
3 . TCR/CD3 complex *3|KbCX  
zx27aZ[  
4. negaive selection of thymocytes \;}dS SB1  
9V~yK?  
5. artificial active immune 0 !Yi.'+  
;I>`!|mT  
6. anti-idiotypic ~0L>l J  
vsK>?5{C-  
7. IgSF %llG/]q#  
j2+&B9 (  
8. Integrin (U)=t$=o  
lG2){){j  
9. chemokine d<]/,BY'  
ws=y*7$y  
10. B7/CD28 H_9~gi  
F)C8LH  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© !)GPI?{^5  
B$)KZR(u  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ 1!~9%=%  
S5j#&i  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ 7Ev~yY;N  
#p^D([k \  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ {2!.3<#  
mV-MJ$3r  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ t ,0~5>5  
)pg?ZM9  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ wDn5|F}i&  
,$*$w<  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ .^/OL}/~<  
\5Hfe;ny-~  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 'C(YUlT2?P  
GZse8ng  
1. B7/CD28 -q[?,h  
3iDRt&y=.  
2. Th1 subset }_K7}] 1  
?>2k>~xlQ  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© gVO[R6C5C  
!iMsTH<  
4. antibody affinity maturation %|UCs8EFm  
jfk`%C Ek=  
5. AP-1 Ok9XC <Xu  
*U8Pjb1  
6. single chain variable fragment£¨ScFv£© _L9`bzZj  
'RXh E  
7. NK cell receptor 7&E3d P  
0:Xvch0  
8. Zinkernagel-Doherty phenomenon UE5T%zd/  
tAefBFu  
9. Ig fold _dj_+<Y?  
0KE+RzrB  
10. CD40/CD40L qy"#XbBeV  
Q YPsqkF*  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© uD_iyK0,  
DR;rK[f  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ m\RU |Z  
IZ/+ROn  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ <`}Oi 5nW  
?Mtd3F^o?  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ nDhr;/"i  
*F[@lY\p  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ !`JaYUL[e  
9KkxUEkW  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ Wxx? iW ,  
]c4?-Vq%u  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ kaq H.e(  
`7[z%cuK  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ ..'k+0u^  
-^yb[b,  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© &@NTedg!  
}8`W%_Yk  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© ?NkweT(  
O eLM*Zi  
1.Co-stimulators (or co-stimulating molecules) '#pY/,hVB  
QhR.8iS  
2.NK-kB ;;;aM:6\  
RvrZ tg5  
3.Immunoglobulin superfamily )lh48Ag0t;  
Vz_ac vfk^  
4.antigen-presenting cell (APC) qRi;[`  
8$9Q=M  
5.death domain @/jLN  
~0/tU# &  
6.CCR and CXCR }(tuBJ9  
qTxw5.Ai!  
7.Lectin (or mitogen) WRIOjQ:  
yR}PC/>  
8.Clusters of differentiation, CD) Q5Yy \M  
wMc/O g  
9.B7 family 6WI-ZEVp&  
5@c/,6l  
10.Cytotoxic T lymphocyte, CTL) Yvmo%.oU  
CcDmZ  
11.IL-15 and IL-15 receptor (IL-15R) tFj[>_d7  
[k<"@[8)  
12.MHC restriction m 0jm$> :Z  
^ &UezDTS  
13.Affinity-chromatography _T\/kJ)Q\  
AlPk o($E*  
14.Cyctosprin A, CsA oY NIJXln  
/i !3Fr"  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) F R57F(31  
%KjvV<f-a  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© gC/~@Z8W]  
4k7 LM]  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 85{2TXQ^%=  
`qXCY^BH2  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ `S)*(s? T  
E: 7R>.g  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ ' ptD`)^(  
]'"aVGqa.  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© '!V5 #J  
K-<kp!v  
ÃâÒßѧרҵ£º {.H FB:<!}  
Q:v9C ^7  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ \gU=B|W  
0`H)c) pP  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ U??T>  
arQEi  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ (>)f#t[9J  
G+k~k/D6  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) NA/hs/ '  
g~/@`Z2Y  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) l)P~#G+C  
yG/_k !{9  
1. ADCC(antibody dependent cell-mediated cytotoxicity) Qzh`x-S  
v:xfGA nP  
2. »·æß¾úËØ(cyclosporin) Cju%CE3a  
^1}Y=! &  
3. KIR(killer cell inhibitory receptor) [BLB xSL  
.I1k+   
4. HLDA(human leucocyte differentiation antigen) wJ}9(>id*  
q33Z.3R  
5. Interleukin 18(IL-18) O9/7?"l"  
jWE?$r"  
6. ÕûºÏËØ(integrin) ==^9_a^  
rL9u7) x  
7. Fas/FasL EWZ?q$  
<<iwJ U%:  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) I}!E r V  
muZ6}&4  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) (imaL,M-D  
W6 y-~  
10. Th1/Th2 P)9$}9i  
QGkMT +A  
11. »ùÒòÒßÃç(DNAÒßÃç) x<lY&KQ0  
,+mH1#-3  
12. chemokines and chemokine receptor =TcT`](o  
NJqjW  
13. ÃâÒßÄÍÊÜ BnwYyh  
s/cclFji]  
14. ¹²´Ì¼¤·Ö×Ó I%#&@  
O% }EpIP_  
15. ËÀÍö½á¹¹Óò(death domain) r}%2;!T  
xoQ;fVNp  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) g)/#gyT4Y  
QY}1i .f  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? 6{8dv9tK  
)o[Jxu'  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠiFBH; O_~  
S9@2-Oc  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î :3 h'Hr  
3{ "MN=  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ +61h!/<W  
5U[ bn=n  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå YuVg/ '=  
|w)S &+  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ ;mtv  
pGHn   
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) 6f^q >YP  
RX6s[uQ  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ vOnhJN  
7!r)[2l  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ WN`|5"?$  
"(cMCBVYdA  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»